<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0003">
 <element-citation publication-type="journal" id="sbref0003">
  <person-group person-group-type="author">
   <name>
    <surname>Cook</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Vermersch</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Comi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Giovannoni</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Rammohan</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Rieckmann</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>SÃ¸rensen</surname>
    <given-names>P.S.</given-names>
   </name>
   <name>
    <surname>Hamlett</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Miret</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Weiner</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Viglietta</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Musch</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Greenberg</surname>
    <given-names>S.J.</given-names>
   </name>
   <collab>CLARITY Study Group</collab>
  </person-group>
  <article-title>Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study</article-title>
  <source>Mult. Scler.</source>
  <volume>17</volume>
  <year>2011</year>
  <fpage>578</fpage>
  <lpage>593</lpage>
  <pub-id pub-id-type="pmid">21228029</pub-id>
 </element-citation>
</ref>
